O

Oppenheimer & Co. Inc.

Global wealth management and investment bank

Regional Director - Northeast Region

Full-Time
$135k - $150k+ Discretionary bonus
Senior
Bachelor's
New York, NY, USA
In PersonRequires travel throughout the Northeast region; approximately 25% to 50% travel.
Sales & Account ManagementField Sales

About the job

Requirements
  • A bachelor's degree in Finance, Business, Marketing, Economics, or a related field.
  • At least 7 years of sales, business development, or relationship management experience within asset management, wealth management, investment consulting, or an investment manager platform.
  • Active FINRA Series 7 and Series 66 registrations are required.
  • A proven track record of meeting or exceeding sales, asset gathering, and business development objectives.
  • Strong knowledge of financial markets, including equities, fixed income, alternative investments, separately managed accounts, model portfolios, and wrap-fee investment programs.
  • Ability to travel approximately 25% to 50% throughout the assigned territory.
Responsibilities
  • Partner with Oppenheimer Financial Advisors to identify client opportunities and drive adoption of OAM investment solutions through presentations, portfolio reviews, and business development initiatives.
  • Develop and execute a territory business plan focused on advisor engagement, asset growth, net asset flows, and achievement of regional sales objectives.
  • Maintain accountability for regional sales activity, advisor engagement, asset growth, and achievement of territory business development goals.
  • Educate and train Financial Advisors on the suite of investment products and solutions available through the OAM platform while driving advisor utilization of OAM offerings.
  • Serve as a subject matter expert on OAM's investment platform, including separately managed accounts, alternative investments, model portfolios, and third-party investment solutions.
  • Build and strengthen relationships with Financial Advisors, OAM colleagues, and third-party investment managers through regular engagement and collaboration.
  • Monitor financial markets and industry developments to provide timely market insights and investment-related guidance to Financial Advisors.
  • Travel throughout the Northeast region to conduct advisor meetings, client presentations, training sessions, and business development activities.
Desired Qualifications
  • Certified Investment Management Analyst, Chartered Financial Analyst, or a similar industry designation.

About the company

O

Oppenheimer & Co. Inc.

View

Oppenheimer & Co. Inc. is a global financial services firm serving clients since 1881, offering wealth management, capital markets, and investment banking. Services include financial planning, equities and fixed income trading and research, and M&A and capital-raising advisory for institutions and mid-market companies. What sets Oppenheimer apart is pairing over a century of experience with tailored, research-driven strategies for individuals and institutions alike. The goal is to help clients grow and protect wealth across market conditions.

Company Size

N/A

Company Stage

IPO

Headquarters

New York City, New York

Founded

1881

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue rose 21.9% to $454.9 million, driven by advisory fees.
  • Public finance momentum accelerated; 2026 competitive underwriting rank improved to No. 18.
  • Hiring seven derivatives specialists and Eric Nortman expanded financing capabilities across institutional clients.

What critics are saying

  • Advisor attrition persists; DFX counted 60 departures and net negative recruiting over 12 months.
  • FINRA disputes remain live; the Brookman expungement battle involved Oppenheimer in 2026.
  • Oppenheimer depends on volatile capital markets; one dry deal cycle quickly compresses revenue and bonuses.

What makes Oppenheimer & Co. Inc. unique

  • Independent broker-dealer with wealth management, investment banking, and 88 U.S. branches.
  • Municipal finance franchise strengthened by Beth Coolidge’s MSRB board seat and hires.
  • Selective advisor platform attracts niche talent, including athlete-focused recruiting and $7.2 billion Next-Gen network.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus

Company News

Yahoo Finance
Oct 28th, 2026
Oppenheimer downgrades Enphase as Q4 revenue guidance of $225M–$255M trails $297M consensus

Oppenheimer downgraded Enphase Energy to Perform from Outperform and removed its price target after the solar equipment maker missed third-quarter expectations and issued weak guidance. Analyst Colin Rusch said a recovery in its core business "is not materializing." Shares fell more than 20% in premarket trading on Wednesday. Third-quarter revenue was $293 million, against consensus of $305 million. Adjusted earnings per share were $0.41, short of the $0.50 expected. Fourth-quarter revenue guidance of $225 million to $255 million fell well below the $297 million consensus. Rusch said price cuts on energy storage are starting to hurt gross margin, and US residential demand remains under pressure from higher interest rates. Oppenheimer cut its 2027 revenue estimate to $885 million from $1.242 billion.

Yahoo Finance
Oct 25th, 2026
Oppenheimer: web and commerce software outlook improves, AI fears linger; Shopify target raised to $205

Interest in web and e-commerce software stocks has improved ahead of third-quarter results, but worries that artificial intelligence could hurt the businesses persist, Oppenheimer said in a note. It expects Shopify's revenue growth to beat Wall Street's 31.6% forecast by 2 to 3 percentage points, helped by strong consumer demand. Oppenheimer raised its price target on the company to $205 from $175. Wix.com is expected to meet forecasts of 10% bookings growth and 12% revenue growth. Weaker demand from smaller designers and partners, as activity shifts to AI tools such as Base44, could delay faster growth. GoDaddy is expected to report bookings growth of 5.0%, in line with forecasts. Commerce.com is expected to report revenue in line with an $83.5 million forecast.

Oppenheimer & Co. Inc.
Oct 1st, 2026
Insights from Oppenheimer's radiopharmaceutical summit.

Insights from Oppenheimer's radiopharmaceutical summit. Oppenheimer & Co. Inc. October 01, 2026 This year, Oppenheimer's 4th Annual Targeted Radiopharmaceutical Therapies Summit, sponsored by Mintz and RSM, convened more than 200 senior biotechnology executives, institutional investors, and key stakeholders from across the radiopharmaceutical therapy ecosystem at Lotte New York Palace in New York City. Hosted and moderated by Oppenheimer Managing Director and Senior Analyst, Jeff Jones, PhD, the summit featured in-depth discussions with industry leaders from over a dozen companies, including AstraZeneca, Novartis, RayzeBio/Bristol Myers Squibb, Aktis Oncology, Perspective Therapeutics, and AdvanCell. Conversations focused on the scientific, clinical, logistical, and commercial factors shaping the next phase of growth in radiopharmaceutical therapies, including product optimization, asset quality, target and isotope selection, and clinical development strategy. The breadth and depth of dialogue reflected the sector's continued maturation, with an estimated 30 clinical-stage companies and ~90 candidates in clinical development, while the only two marketed products today generated ~$3B in 2025 revenue. Companies are increasingly concentrating on differentiated assets, broadening the scope of the opportunity, refining product profiles, and maximizing long-term value creation. This year's inclusion of pharmaceutical industry leaders further underscored the growing strategic importance of radiopharmaceutical therapies within the broader biopharmaceutical landscape. Panelists offered valuable perspectives on partnership activity, business development priorities, and the increasingly important role of radiopharmaceuticals in long-term portfolio strategies. As interest in the sector continues to accelerate, the summit served as an important forum for exchanging ideas, sharing perspectives, and exploring the developments shaping the future of radiopharmaceutical therapies. Oppenheimer remains committed to convening industry leaders and delivering differentiated insights on emerging areas of innovation across healthcare and life sciences. Oppenheimer Holdings, Inc. thank its speakers, panelists, attendees, and partners for contributing to another successful summit and look forward to continuing the conversation as the radiopharmaceutical therapy landscape evolves.

Yahoo Finance
Sep 30th, 2026
Oppenheimer tips FuelCell Energy and Innoviva for 66% gains on AI power and healthcare growth

Oppenheimer has identified two stocks with significant upside potential: FuelCell Energy and Innoviva. The investment bank sees gains of up to 66% over the next 12 months. FuelCell Energy, which develops modular fuel-cell systems for commercial and industrial customers, received an Outperform rating with a $24 price target, implying 42% upside from $16.90. Analyst Colin Rusch believes the company's technology positions it to benefit from growing data-centre electricity demand. FuelCell announced an agreement with Fit Energy in June involving up to 380 megawatts of capacity. Innoviva, which combines respiratory drug royalties with critical-care and infectious-disease treatments, was given a $35 price target, suggesting 66% upside from $21.11. Analyst Les Sulewski notes the company's specialty therapeutics business delivered 26% year-over-year growth in US product sales to $36.6 million during the second quarter.

Yahoo Finance
Sep 30th, 2026
Oppenheimer names top software stocks as AI spending shifts from adoption to ROI focus

Oppenheimer analysts say AI in software has moved beyond experimentation, with companies now required to demonstrate measurable returns on investment. AI is becoming a recurring operating expense, with chief financial officers evaluating investments alongside labour costs. The firm says system-of-record vendors and businesses with seat-plus-consumption pricing models are best positioned to benefit. These models offer protection against disruption and the clearest path to AI-driven growth. Oppenheimer's top picks include Microsoft Corporation, citing accelerating platform demand and over $1 billion in AI-related revenue. ServiceNow is highlighted for its exposure to automation and security tailwinds, also exceeding $1 billion in AI revenue. Braze is noted as a system-of-record for customer engagement with durable competitive advantages.